1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportunity Analysis and Forecasts to 2026

  • July 2017
  • 395 pages
  • GlobalData
Report ID: 5103462

Summary

Table of Contents

Search Inside

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportunity Analysis and Forecasts to 2026

Summary
Acute myeloid leukemia (AML) is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. Although a number of acquired genetic and molecular abnormalities have been implicated in the manifestation of AML and disease progression, in most cases the stimuli causing these abnormalities to occur have not been identified.

Major drivers of the AML market in the 7MM will include an increasing number of elderly incident cases of AML, particularly in the US, the launch of premium-priced therapies, including AbbVie/Roche’s Venclexta, Celgene’s enasidenib and CC-486, and Actinium’s Iomab-B for elderly AML patients; Daiichi Sankyo’s quizartinib and Astellas’ gilteritinib for FLT3-mutated AML; and Jazz’s Vyxeos for newly diagnosed elderly secondary AML patients, and an increasing branded drug treatment rate, particularly among elderly patients.

Barriers to the growth of the AML market in the 7MM will include a high enrollment rate of AML patients in clinical trials in the 5EU, the US, and Japan, pressure for cost-consciousness, particularly in the EU, limited adoption of the branded therapies due to positioning of most of them in combination with the relatively toxic current standard-of-care (SOC) regimens, loss of patent protection of Vidaza, Dacogen, Rydapt, and the prospective branded therapies Vyxeos and guadecitabine.

Key Questions Answered
- The AML market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AML market?
- How will new pipeline agents such as Rydapt, enasidenib, Mylotarg, Vyxeos, and Venclexta impact the AML market?
- The current AML market is dominated by generic chemotherapies. How will the advent of targeted prescription drugs change the drug treatment landscape in AML? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?

Scope
- Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments , forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AML therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AML. The most promising candidate in Phase III development are profiled.
- Analysis of the current and future market competition in the global AML market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AML market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AML market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

  • $ 7995
  • Industry report
  • August 2017
  • by GlobalData

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities Summary Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, ...

Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need

  • $ 6995
  • Industry report
  • August 2017
  • by GBI Research

Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant ...

Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

  • $ 6995
  • Industry report
  • September 2017
  • by GBI Research

Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets Summary Cancer is a group of diseases that are defined by abnormal cell growth, local ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.